Lantheus (NASDAQ:LNTH) Posts Earnings Results, Misses Expectations By $0.23 EPS

Lantheus (NASDAQ:LNTH) released its quarterly earnings data on Wednesday. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.23), Zacks reports. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. Lantheus updated its FY 2025 guidance to 7.000-7.200 EPS.

Lantheus Stock Performance

NASDAQ:LNTH traded up $14.16 during mid-day trading on Wednesday, reaching $94.21. The stock had a trading volume of 1,894,415 shares, compared to its average volume of 856,048. The stock has a market capitalization of $6.55 billion, a P/E ratio of 15.67 and a beta of 0.44. Lantheus has a one year low of $56.44 and a one year high of $126.89. The firm has a 50 day moving average price of $89.77 and a two-hundred day moving average price of $96.81.

Analyst Upgrades and Downgrades

LNTH has been the subject of a number of recent analyst reports. StockNews.com cut shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Truist Financial reaffirmed a “buy” rating and set a $120.00 price objective (down from $135.00) on shares of Lantheus in a research report on Friday, November 8th. JMP Securities reaffirmed a “market outperform” rating and issued a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. Finally, The Goldman Sachs Group began coverage on Lantheus in a research report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $131.86.

Insider Buying and Selling at Lantheus

In related news, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the sale, the director now directly owns 33,207 shares in the company, valued at approximately $3,146,695.32. This trade represents a 2.92 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.50% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.